These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 20473593)

  • 21. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera.
    Zhang S; Qiu H; Fischer BS; Li W; Duan L; Sun X; Xu W; Li J
    Leuk Lymphoma; 2008 Apr; 49(4):696-9. PubMed ID: 18398736
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H
    Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Hematology; 2008 Apr; 13(2):71-6. PubMed ID: 18616871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia.
    Tarkun P; Mehtap O; Atesoğlu EB; Geduk A; Musul MM; Hacihanefioglu A
    Eur J Haematol; 2013 Sep; 91(3):228-235. PubMed ID: 23731455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children.
    Ismael O; Shimada A; Hama A; Sakaguchi H; Doisaki S; Muramatsu H; Yoshida N; Ito M; Takahashi Y; Akita N; Sunami S; Ohtsuka Y; Asada Y; Fujisaki H; Kojima S
    Pediatr Blood Cancer; 2012 Sep; 59(3):530-5. PubMed ID: 22106054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
    Poodt J; Fijnheer R; Walsh IB; Hermans MH
    Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.
    Vannucchi AM; Antonioli E; Guglielmelli P; Rambaldi A; Barosi G; Marchioli R; Marfisi RM; Finazzi G; Guerini V; Fabris F; Randi ML; De Stefano V; Caberlon S; Tafuri A; Ruggeri M; Specchia G; Liso V; Rossi E; Pogliani E; Gugliotta L; Bosi A; Barbui T
    Blood; 2007 Aug; 110(3):840-6. PubMed ID: 17379742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thrombosis among 1537 patients with JAK2
    Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
    Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in advanced oxidation protein products, advanced glycation end products, and s-nitrosylated proteins, in patients affected by polycythemia vera and essential thrombocythemia.
    Musolino C; Allegra A; Saija A; Alonci A; Russo S; Spatari G; Penna G; Gerace D; Cristani M; David A; Saitta S; Gangemi S
    Clin Biochem; 2012 Nov; 45(16-17):1439-43. PubMed ID: 22850610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
    Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
    Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients.
    Yoo EH; Park KJ; Won HH; Park JH; Park JH; Lee ST; Kim HJ; Bang SM; Chi HS; Jung CW; Kim SH; Yun H; Sun CH; Park I; Lee S; Lee C; Merriman B; Luo R; Tan EH; Park KJ; Yoo NK; Kang JJ; Kim JW
    J Clin Lab Anal; 2016 Nov; 30(6):1061-1070. PubMed ID: 27132877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.
    Rudzki Z; Sacha T; Stój A; Czekalska S; Wójcik M; Skotnicki AB; Grabowska B; Zduńczyk A; Okoń K; Stachura J
    Int J Hematol; 2007 Aug; 86(2):130-6. PubMed ID: 17875526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
    Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
    Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
    PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2(V617F) mutational status.
    Ohyashiki K; Akahane D; Gotoh A; Ito Y; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
    Leukemia; 2007 Dec; 21(12):2544-5. PubMed ID: 17611562
    [No Abstract]   [Full Text] [Related]  

  • 39. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera.
    Marchetti M; Castoldi E; Spronk HM; van Oerle R; Balducci D; Barbui T; Rosing J; Ten Cate H; Falanga A
    Blood; 2008 Nov; 112(10):4061-8. PubMed ID: 18768782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.